The United Laboratories International Holdings Limited (3933.HK)
HKD 13.94
(0.29%)
HKD 13.94
(0.29%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.3 Billion CNY | 18.94% |
| 2022 | 1.09 Billion CNY | 395.36% |
| 2021 | 221.21 Million CNY | -83.08% |
| 2020 | 1.3 Billion CNY | -46.06% |
| 2019 | 2.42 Billion CNY | 53.03% |
| 2018 | 1.58 Billion CNY | -52.27% |
| 2017 | 3.31 Billion CNY | 65.98% |
| 2016 | 1.99 Billion CNY | 161.42% |
| 2015 | 764.59 Million CNY | -34.46% |
| 2014 | 1.16 Billion CNY | -0.13% |
| 2013 | 1.16 Billion CNY | 41.82% |
| 2012 | 823.66 Million CNY | 7.91% |
| 2011 | 763.27 Million CNY | 0.0% |
| 2010 | - CNY | -100.0% |
| 2009 | 755.35 Million CNY | 102.0% |
| 2008 | 373.94 Million CNY | -26.5% |
| 2007 | 508.78 Million CNY | 23.09% |
| 2006 | 413.34 Million CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 1.43 Billion CNY | 0.0% |
| 2023 Q2 | 880 Million CNY | 0.0% |
| 2023 Q4 | 1.3 Billion CNY | 0.0% |
| 2023 FY | 1.3 Billion CNY | 18.94% |
| 2022 Q4 | 1.09 Billion CNY | 0.0% |
| 2022 FY | 1.09 Billion CNY | 395.36% |
| 2022 Q2 | 482.19 Million CNY | 0.0% |
| 2021 Q2 | 907.18 Million CNY | 0.0% |
| 2021 FY | 221.21 Million CNY | -83.08% |
| 2021 Q4 | 221.21 Million CNY | 0.0% |
| 2020 Q2 | 2.41 Billion CNY | 0.0% |
| 2020 Q4 | 1.3 Billion CNY | 0.0% |
| 2020 FY | 1.3 Billion CNY | -46.06% |
| 2019 Q2 | 604.82 Million CNY | 0.0% |
| 2019 FY | 2.42 Billion CNY | 53.03% |
| 2019 Q4 | 2.42 Billion CNY | 0.0% |
| 2018 Q2 | 3.05 Billion CNY | 0.0% |
| 2018 Q4 | 1.58 Billion CNY | 0.0% |
| 2018 FY | 1.58 Billion CNY | -52.27% |
| 2017 FY | 3.31 Billion CNY | 65.98% |
| 2017 Q4 | 3.31 Billion CNY | 0.0% |
| 2017 Q2 | 2.9 Billion CNY | 0.0% |
| 2016 Q4 | 1.99 Billion CNY | 0.0% |
| 2016 FY | 1.99 Billion CNY | 161.42% |
| 2016 Q2 | 1.25 Billion CNY | 0.0% |
| 2015 FY | 764.59 Million CNY | -34.46% |
| 2015 Q2 | 1.08 Billion CNY | 0.0% |
| 2015 Q4 | 764.59 Million CNY | 0.0% |
| 2014 Q2 | 1.18 Billion CNY | 0.0% |
| 2014 Q4 | 1.16 Billion CNY | 0.0% |
| 2014 FY | 1.16 Billion CNY | -0.13% |
| 2013 Q2 | 1.2 Billion CNY | 0.0% |
| 2013 FY | 1.16 Billion CNY | 41.82% |
| 2013 Q4 | 1.69 Billion CNY | 0.0% |
| 2012 Q2 | 1.3 Billion CNY | 0.0% |
| 2012 Q4 | 823.66 Million CNY | 0.0% |
| 2012 FY | 823.66 Million CNY | 7.91% |
| 2011 Q4 | 763.27 Million CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2011 FY | 763.27 Million CNY | 0.0% |
| 2010 Q4 | - CNY | 0.0% |
| 2010 FY | - CNY | -100.0% |
| 2010 Q2 | 501.58 Million CNY | 0.0% |
| 2009 Q4 | 755.35 Million CNY | 0.0% |
| 2009 FY | 755.35 Million CNY | 102.0% |
| 2008 FY | 373.94 Million CNY | -26.5% |
| 2007 FY | 508.78 Million CNY | 23.09% |
| 2006 FY | 413.34 Million CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 2.07 Million HKD | -62771.328% |
| Grand Pharmaceutical Group Limited | 990.02 Million HKD | -31.645% |
| Extrawell Pharmaceutical Holdings Limited | 117.12 Million HKD | -1012.771% |
| Wai Yuen Tong Medicine Holdings Limited | 276.2 Million HKD | -371.876% |
| Qianhai Health Holdings Limited | - HKD | -Infinity% |
| Lee's Pharmaceutical Holdings Limited | 70.63 Million HKD | -1745.124% |
| Essex Bio-Technology Limited | 36.05 Million HKD | -3514.643% |
| Tongfang Kontafarma Holdings Limited | 12.8 Million HKD | -10081.408% |
| PuraPharm Corporation Limited | 81.09 Million HKD | -1507.194% |
| SSY Group Limited | 1.94 Billion HKD | 33.08% |
| JBM (Healthcare) Limited | 43.8 Million HKD | -2875.621% |
| Jacobson Pharma Corporation Limited | 592.2 Million HKD | -120.081% |
| China Resources Pharmaceutical Group Limited | 16.61 Billion HKD | 92.157% |